Prothena Co. plc (NASDAQ:PRTA) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC decreased its holdings in Prothena Co. plc (NASDAQ:PRTA) by 40.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 900 shares of the biotechnology company’s stock after selling 610 shares during the period. Nisa Investment Advisors LLC’s holdings in Prothena were worth $33,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in Prothena by 99.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,375 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 684 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Prothena during the third quarter worth approximately $74,000. Allspring Global Investments Holdings LLC lifted its stake in Prothena by 58.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,096 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 1,140 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Prothena by 12.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,464 shares of the biotechnology company’s stock worth $360,000 after acquiring an additional 797 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in shares of Prothena by 3.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 7,908 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 295 shares during the last quarter. 97.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Prothena

In other Prothena news, CAO Karin L. Walker sold 5,000 shares of the business’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $34.00, for a total value of $170,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 28.10% of the company’s stock.

Prothena Price Performance

Shares of NASDAQ:PRTA opened at $21.29 on Tuesday. The firm has a fifty day moving average price of $25.78 and a 200 day moving average price of $32.49. Prothena Co. plc has a 1-year low of $20.42 and a 1-year high of $79.65. The stock has a market cap of $1.14 billion, a P/E ratio of -7.60 and a beta of 0.21.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.03). Prothena had a negative net margin of 160.91% and a negative return on equity of 24.84%. The company had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $2.15 million. During the same period in the prior year, the company earned $0.12 earnings per share. The firm’s revenue was down 99.4% on a year-over-year basis. Sell-side analysts expect that Prothena Co. plc will post -4.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PRTA. Oppenheimer lowered their target price on shares of Prothena from $98.00 to $80.00 and set an “outperform” rating for the company in a research note on Tuesday, February 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Prothena in a research report on Wednesday, April 10th. JMP Securities increased their price target on shares of Prothena from $81.00 to $85.00 and gave the company a “market outperform” rating in a research note on Friday, February 16th. StockNews.com cut shares of Prothena from a “hold” rating to a “sell” rating in a report on Monday, February 19th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $38.00 target price (down from $68.00) on shares of Prothena in a research report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $69.63.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.